Institute For Rare Diseases Research News Today

Preliminary study of messenger RNA therapy against propionic acidaemia shows it is safe, but doubts remain about its usefulness

Target validation is a crucial step in pre-clinical drug discovery workflows that builds confidence on the identification of a genetic target as relevant to a disease. With recent advancements, CRISPR serves as a particularly powerful tool for this process, as it enables researchers to accurately modify genes and determine their function in a variety of experimental systems.

Target validation is a crucial step in pre-clinical drug discovery workflows that builds confidence on the identification of a genetic target as relevant to a disease. With recent advancements, CRISPR serves as a particularly powerful tool for this process, as it enables researchers to accurately modify genes and determine their function in a variety of experimental systems.

Target validation is a crucial step in pre-clinical drug discovery workflows that builds confidence on the identification of a genetic target as relevant to a disease. With recent advancements, CRISPR serves as a particularly powerful tool for this process, as it enables researchers to accurately modify genes and determine their function in a variety of experimental systems.

See how researchers are using CRISPR to uncover the mechanisms of retinal degeneration for future interventions

See how researchers are using CRISPR to uncover the mechanisms of retinal degeneration for future interventions

See how alternative animal models created via CRISPR gene editing are helping the study of rare and ultra-rare diseases